Related Tags >> Onyx Pharmaceuticals Ardea BioSciences Nexavar biotechnology company

Bayer Healthcare News

Most Popular Bayer Healthcare Story

Bayer details positive PhIII data on cancer blockbuster hopeful regorafenib

January 18, 2012 — 10:38am ET | By John Carroll

Bayer HealthCare took another step toward a planned marketing application for the cancer drug regorafenib today as it unveiled the late-stage colorectal cancer data that it plans to take to Read more...

Bayer Healthcare Press Releases

Latest Headlines

Bayer details positive PhIII data on cancer blockbuster hopeful regorafenib
January 18, 2012
Onyx Pharma shares soar on report of its hunt for options, acquirers
November 29, 2011
FDA pins approval on Regeneron eye drug Eylea
November 18, 2011
Bayer settles Onyx spat with $160M payout, sales rights and royalties
October 12, 2011
What's the best strategy for working with FDA regulators?
June 15, 2011
Algeta shares spike on promising prostate cancer drug data
June 6, 2011
Bayer CEO sketches the perfect takeover target
May 4, 2011
Bayer looks to JVs, not buys, for Indian growth
March 1, 2011
Philogen cancels IPO after Bayer pulls out of cancer deal
February 15, 2011
Bayer's regorafenib gets orphan drug designation
February 4, 2011
Regeneron gets $10M milestone on Phase III results
December 20, 2010
Bayer will cap R&D budget at $4.1B
December 8, 2010
Xarelto researchers wow analysts with blockbuster PhIII data
November 15, 2010
Bayer, Kythera ink $373M dermatology deal
August 31, 2010
Xarelto matches standard in head-to-head blood clot trial
August 5, 2010
Bayer to open biotech Innovation Center in Pfizer's old SF digs
May 18, 2010
Xarelto approval hopes revived?
November 19, 2009
Bayer exec says company will hike R&D spending
November 12, 2009
Regeneron gets $20M milestone from Bayer
July 24, 2009
FDA asks for more data on Xarelto
May 28, 2009

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events